Literature DB >> 29778554

Cumulative live birth rates after IVF in patients with polycystic ovaries: phenotype matters.

Michel De Vos1, Stéphanie Pareyn2, Panagiotis Drakopoulos2, José M Raimundo2, Ellen Anckaert3, Samuel Santos-Ribeiro2, Nikolaos P Polyzos2, Herman Tournaye2, Christophe Blockeel4.   

Abstract

RESEARCH QUESTION: Do cumulative live birth rates (CLBR) vary among women with different polycystic ovary syndrome (PCOS) phenotypes who undergo IVF/intracytoplasmic sperm injection (ICSI) treatment?
DESIGN: In this retrospective cohort study, data from 567 patients undergoing an assisted reproductive technology (ART) cycle between January 2010 and December 2015 were collected. Demographical traits, cycle characteristics and clinical and laboratory data were analysed.
RESULTS: After conventional ovarian stimulation using a gonadotrophin-releasing hormone antagonist protocol, the median number of oocytes retrieved ranged between 11 and 13.5 and did not differ significantly among the studied groups. Live birth rate (LBR) after fresh embryo transfer and CLBR after transfer of all fresh and vitrified embryos were significantly lower in women with hyperandrogenic PCOS phenotypes A (LBR 16.7%, CLBR 25.8%) and C (LBR 18.5%, CLBR 27.8%) compared with women with normoandrogenic PCOS phenotype D (LBR 33.7%, CLBR 48%) (P-value for LBR 0.01 and 0.03, respectively; P-value for CLBR 0.002 and 0.01, respectively) and controls with a polycystic ovarian morphology (LBR 37.1%, CLBR 53.3%) (P-value for LBR 0.002 and 0.01, respectively; P-value for CLBR <0.001 and 0.001, respectively). Multivariate regression analysis indicated that after adjustment for relevant confounders, PCOS phenotype was an independent predictor for CLBR.
CONCLUSIONS: Hyperandrogenic PCOS phenotypes confer significantly lower CLBR compared with their normoandrogenic counterparts. These findings may imply the need for adapted counselling and tailored approaches when treating PCOS patients with hyperandrogenism who require ART.
Copyright © 2018 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Assisted reproductive technology; Cumulative live birth rate; Hyperandrogenism; PCOM; PCOS

Mesh:

Substances:

Year:  2018        PMID: 29778554     DOI: 10.1016/j.rbmo.2018.05.003

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  13 in total

Review 1.  Antioxidant supplementations ameliorate PCOS complications: a review of RCTs and insights into the underlying mechanisms.

Authors:  Roghaye Gharaei; Forough Mahdavinezhad; Esmaeil Samadian; Jahanbakhsh Asadi; Zhaleh Ashrafnezhad; Ladan Kashani; Fardin Amidi
Journal:  J Assist Reprod Genet       Date:  2021-11       Impact factor: 3.412

2.  Randomized controlled trial of astaxanthin impacts on antioxidant status and assisted reproductive technology outcomes in women with polycystic ovarian syndrome.

Authors:  Roghaye Gharaei; Ashraf Alyasin; Forough Mahdavinezhad; Esmaeil Samadian; Zhaleh Ashrafnezhad; Fardin Amidi
Journal:  J Assist Reprod Genet       Date:  2022-03-03       Impact factor: 3.357

3.  A comparison of IVF outcomes transferring a single ideal blastocyst in women with polycystic ovary syndrome and normal ovulatory controls.

Authors:  Naama Steiner; Senem Ates; Talya Shaulov; Guy Shrem; Alexander Volodarsky-Perel; S Yehuda Dahan; Samer Tannus; Weon-Young Son; Michael H Dahan
Journal:  Arch Gynecol Obstet       Date:  2020-07-15       Impact factor: 2.344

4.  Sporadic anovulation is not an important determinant of becoming pregnant and time to pregnancy among eumenorrheic women: A simulation study.

Authors:  Elizabeth A DeVilbiss; Joseph B Stanford; Sunni L Mumford; Lindsey A Sjaarda; Keewan Kim; Jessica R Zolton; Neil J Perkins; Enrique F Schisterman
Journal:  Paediatr Perinat Epidemiol       Date:  2020-09-24       Impact factor: 3.103

5.  Polycystic ovary syndrome phenotype does not have impact on oocyte morphology.

Authors:  Audrey Uk; Christine Decanter; Camille Grysole; Laura Keller; Hélène Béhal; Mauro Silva; Didier Dewailly; Geoffroy Robin; Anne-Laure Barbotin
Journal:  Reprod Biol Endocrinol       Date:  2022-01-05       Impact factor: 5.211

6.  Comparison of Cumulative Live Birth Rate Between Aged PCOS Women and Controls in IVF/ICSI Cycles.

Authors:  Zhuoyao Mai; Manlin Liu; Ping Pan; Lin Li; Jia Huang; Xiaoli Chen; Dongzi Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-28       Impact factor: 5.555

7.  High Serum Anti-Müllerian Hormone Concentrations Are Associated With Poor Pregnancy Outcome in Fresh IVF/ICSI Cycle but Not Cumulative Live Birth Rate in PCOS Patients.

Authors:  Yaxin Guo; Shuai Liu; Shiqiao Hu; Fei Li; Lei Jin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-26       Impact factor: 5.555

Review 8.  Perspectives on the development and future of oocyte IVM in clinical practice.

Authors:  Michel De Vos; Michaël Grynberg; Tuong M Ho; Ye Yuan; David F Albertini; Robert B Gilchrist
Journal:  J Assist Reprod Genet       Date:  2021-07-03       Impact factor: 3.412

9.  High serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology.

Authors:  Reshef Tal; Charles M Seifer; Moisey Khanimov; David B Seifer; Oded Tal
Journal:  Reprod Biol Endocrinol       Date:  2020-03-10       Impact factor: 5.211

10.  Growth hormone alleviates oxidative stress and improves oocyte quality in Chinese women with polycystic ovary syndrome: a randomized controlled trial.

Authors:  Yan Gong; Shan Luo; Ping Fan; Song Jin; Huili Zhu; Tang Deng; Yi Quan; Wei Huang
Journal:  Sci Rep       Date:  2020-10-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.